Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Multiple Sclerosis

  Free Subscription


4 BMC Neurol
3 Brain
1 Can J Neurol Sci
1 J Neuroimmunol
3 J Neurol
1 J Neurol Neurosurg Psychiatry
1 J Neurol Sci
2 Lancet Neurol
13 Mult Scler
1 Neurol Clin Pract
4 Neurology
2 PLoS One
1 Rev Neurol (Paris)

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Neurol

  1. SPERBER PS, Brandt AU, Zimmermann HG, Bahr LS, et al
    Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study.
    BMC Neurol. 2022;22:479.
    PubMed         Abstract available

  2. MEYER-MOOCK S, Raths S, Strunk K, Siebert B, et al
    Strengthening the occupational and social participation of multiple sclerosis patients - design of a multicenter, parallel-group randomized controlled trial (MSnetWork-study).
    BMC Neurol. 2022;22:472.
    PubMed         Abstract available

  3. SALMANI S, Mousavi SH, Navardi S, Hosseinzadeh F, et al
    The barriers and facilitators to health-promoting lifestyle behaviors among people with multiple sclerosis during the coronavirus disease 2019 pandemic: a content analysis study.
    BMC Neurol. 2022;22:490.
    PubMed         Abstract available

  4. MARTIKAINEN MH, Suomela M, Majamaa K
    Magnetic resonance imaging negative myelopathy in Leber's hereditary optic neuropathy: a case report.
    BMC Neurol. 2022;22:487.
    PubMed         Abstract available


  5. PISA M, Pansieri J, Yee S, Ruiz J, et al
    Anterior optic pathway pathology in CNS demyelinating diseases.
    Brain. 2022;145:4308-4319.
    PubMed         Abstract available

  6. JAMES BATES RE, Browne E, Schalks R, Jacobs H, et al
    Lymphotoxin-alpha expression in the meninges causes lymphoid tissue formation and neurodegeneration.
    Brain. 2022;145:4287-4307.
    PubMed         Abstract available

  7. NIJ BIJVANK JA, Hof SN, Prouskas SE, Schoonheim MM, et al
    A novel eye-movement impairment in multiple sclerosis indicating wide-spread cortical damage.
    Brain. 2022 Dec 20:awac474. doi: 10.1093.
    PubMed         Abstract available

    Can J Neurol Sci

  8. MORROW SA, Baldwin C, Alkabie S
    Importance of Identifying Cognitive Impairment in Multiple Sclerosis.
    Can J Neurol Sci. 2022 Dec 12:1-23. doi: 10.1017/cjn.2022.

    J Neuroimmunol

  9. CURRAN C, Vaitaitis G, Waid D, Volmer T, et al
    Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS).
    J Neuroimmunol. 2022;374:578008.
    PubMed         Abstract available

    J Neurol

  10. SEN MK, Hossain MJ, Mahns DA, Brew BJ, et al
    Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.
    J Neurol. 2022 Dec 15. doi: 10.1007/s00415-022-11507.
    PubMed         Abstract available

  11. ALBERGONI M, Storelli L, Preziosa P, Rocca MA, et al
    The insula modulates the effects of aerobic training on cardiovascular function and ambulation in multiple sclerosis.
    J Neurol. 2022 Dec 12:1-10. doi: 10.1007/s00415-022-11513.
    PubMed         Abstract available

  12. LOONSTRA FC, Falize KF, de Ruiter LRJ, Schoonheim MM, et al
    Adipokines in multiple sclerosis patients are related to clinical and radiological measures.
    J Neurol. 2022 Dec 23. doi: 10.1007/s00415-022-11519.
    PubMed         Abstract available

    J Neurol Neurosurg Psychiatry

  13. AIELLO A, Coppola A, Ruggieri S, Farroni C, et al
    Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.
    J Neurol Neurosurg Psychiatry. 2022 Dec 15:jnnp-2022-330175.
    PubMed         Abstract available

    J Neurol Sci

  14. ETEMADIFAR M, Abhari AP, Nouri H, Eighani N, et al
    Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
    J Neurol Sci. 2022;444:120518.
    PubMed         Abstract available

    Lancet Neurol

  15. BENNETT JL, Costello F, Chen JJ, Petzold A, et al
    Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment.
    Lancet Neurol. 2022 Sep 22. pii: S1474-4422(22)00187.
    PubMed         Abstract available

    Multiple sclerosis in 2022: old players, new insights.
    Lancet Neurol. 2023;22:19-21.

    Mult Scler

  17. KRAJNC N, Dal-Bianco A, Leutmezer F, Kasprian G, et al
    Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis.
    Mult Scler. 2022 Dec 20:13524585221138486. doi: 10.1177/13524585221138486.
    PubMed         Abstract available

  18. HEGEN H, Arrambide G, Gnanapavan S, Kaplan B, et al
    Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.
    Mult Scler. 2022 Dec 17:13524585221134217. doi: 10.1177/13524585221134217.
    PubMed         Abstract available

  19. LONGONI G, Martinez Chavez E, Young K, Brown RA, et al
    Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis.
    Mult Scler. 2022 Dec 22:13524585221137500. doi: 10.1177/13524585221137500.
    PubMed         Abstract available

  20. JAKIMOVSKI D, Kavak KS, Zakalik K, Coetzee T, et al
    Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC).
    Mult Scler. 2022 Dec 22:13524585221140271. doi: 10.1177/13524585221140271.
    PubMed         Abstract available

  21. TSAGKAS C, Huck-Horvath A, Cagol A, Haas T, et al
    Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
    Mult Scler. 2022 Dec 22:13524585221139152. doi: 10.1177/13524585221139152.
    PubMed         Abstract available

  22. FOX RJ, Tervonen T, Phillips-Beyer A, Sidorenko T, et al
    The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
    Mult Scler. 2022 Dec 22:13524585221140270. doi: 10.1177/13524585221140270.
    PubMed         Abstract available

  23. OKUDA DT, Stanley T, McCreary M, Smith A, et al
    Selective vulnerability of brainstem and cervical spinal cord regions in people with non-progressive multiple sclerosis of Black or African American and European ancestry.
    Mult Scler. 2022 Dec 12:13524585221139575. doi: 10.1177/13524585221139575.
    PubMed         Abstract available

  24. ABDEL-MANNAN O, Ciccarelli O
    Is the central vein sign a useful diagnostic marker for paediatric-onset multiple sclerosis?
    Mult Scler. 2022 Dec 13:13524585221142318. doi: 10.1177/13524585221142318.

  25. BOCCIA VD, Lapucci C, Cellerino M, Tazza F, et al
    Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study.
    Mult Scler. 2022 Dec 13:13524585221142319. doi: 10.1177/13524585221142319.
    PubMed         Abstract available

    A role for HLA in mediating long-term multiple sclerosis outcomes?
    Mult Scler. 2022 Dec 14:13524585221139767. doi: 10.1177/13524585221139767.

  27. DE MEO E, Portaccio E
    It is time to define cognitive phenotypes in multiple sclerosis.
    Mult Scler. 2022 Dec 14:13524585221141263. doi: 10.1177/13524585221141263.

  28. SABATHE C, Casey R, Vukusic S, Leray E, et al
    Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
    Mult Scler. 2022 Dec 14:13524585221139156. doi: 10.1177/13524585221139156.
    PubMed         Abstract available

  29. CALVI A, Clarke MA, Prados F, Chard D, et al
    Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis.
    Mult Scler. 2022 Dec 14:13524585221141964. doi: 10.1177/13524585221141964.
    PubMed         Abstract available

    Neurol Clin Pract

  30. ABDEL MAGID HS, Jin S, Culpepper WJ, Nelson LM, et al
    Telemedicine Utilization Among Patients With Multiple Sclerosis in the US Veterans Health Administration, 2010-2020.
    Neurol Clin Pract. 2022;12:e133-e142.
    PubMed         Abstract available


  31. BERGSLAND N, Dwyer MG, Jakimovski D, Tavazzi E, et al
    Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000201608.
    PubMed         Abstract available

  32. BOFFA G, Signori A, Massacesi L, Mariottini A, et al
    Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206750.
    PubMed         Abstract available

  33. MULLER J, Noteboom S, Granziera C, Schoonheim MM, et al
    Understanding the Role of the Choroid Plexus in Multiple Sclerosis as an MRI Biomarker of Disease Activity.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206806.

  34. MULLER-JENSEN L, Kriedemann H, Anvari K, Huehnchen P, et al
    Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
    Neurology. 2022 Dec 20:10.1212/WNL.0000000000206743.

    PLoS One

  35. CLARKSON TC, Iguchi N, Xie AX, Malykhina AP, et al
    Differential transcriptomic changes in the central nervous system and urinary bladders of mice infected with a coronavirus.
    PLoS One. 2022;17:e0278918.
    PubMed         Abstract available

  36. AL-KAFAJI G, Alwehaidah MS, Alsabbagh MM, Alharbi MA, et al
    Mitochondrial DNA haplogroup analysis in Saudi Arab patients with multiple sclerosis.
    PLoS One. 2022;17:e0279237.
    PubMed         Abstract available

    Rev Neurol (Paris)

  37. CICCONE A, Mathey G, Prunis C, Debouverie M, et al
    Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod.
    Rev Neurol (Paris). 2022 Dec 7:S0035-3787(22)00824.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.